clinical trial · NCT06400485
AMT-676 in Patients With Advanced Solid Tumors
Advanced Solid TumorsAMT-676
brief summary
This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.
started
Jun 18, 2024
primary completion
May 15, 2027
completion
Dec 31, 2027
last updated
May 18, 2026
official title
First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol